Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance

PURPOSE: Enzalutamide is a second-generation androgen receptor (AR) inhibitor which has improved overall survival (OS) in metastatic castration resistant prostate cancer (CRPC). However, nearly all patients develop resistance. We designed a phase 2 multicenter study of enzalutamide in metastatic CRP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: McKay, Rana R., Kwak, Lucia, Crowdis, Jett P., Sperger, Jamie M., Zhao, Shuang G., Xie, Wanling, Werner, Lillian, Lis, Rosina, Zhang, Zhenwei, Wei, Xiao X., Lang, Joshua M., Van Allen, Eliezer M., Bhatt, Rupal S., Yu, Evan Y., Nelson, Peter S., Bubley, Glenn J., Montgomery, R. Bruce, Taplin, Mary-Ellen
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8254786/
https://ncbi.nlm.nih.gov/pubmed/33849963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4616
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados